Bolt Biotherapeutics today announced a protocol update for its next‑generation Boltbody ISAC candidate BDC‑4182, a Phase 1 dose‑escalation study targeting claudin 18.2 in gastric and gastroesophageal cancer patients. The company will modify the trial to allow step‑up dosing, a strategy that has proven effective for T‑cell engagers, and expects to report initial clinical data in the third quarter of 2026.
In addition to the clinical update, Bolt disclosed a 50% workforce reduction aimed at conserving capital. The company now projects its cash runway to extend into 2027, a move that follows the announcement of the protocol change and reflects a renewed focus on accelerating BDC‑4182’s development while maintaining financial sustainability. President and CEO Willie Quinn said, “We are committed to advancing BDC‑4182 and supporting our ISAC collaborations to increase shareholder value.”
The announcement underscores Bolt’s strategic pivot toward its most promising assets. With the protocol modification, the company aims to enhance the therapeutic window of BDC‑4182, while the extended runway provides the time needed to secure a partnership for its Dectin‑2 agonist BDC‑3042 and to continue supporting existing ISAC collaborations with Genmab and Toray. These steps position Bolt to accelerate its pipeline and potentially bring a differentiated immunotherapy to market in the coming years.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.